Silk Road Medical, Inc (SILK)

Market Cap	1.12B
Revenue (ttm)	191.43M
Net Income (ttm)	-56.54M
Shares Out	40.63M
EPS (ttm)	-1.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	27.49
Day's Range	27.49 - 27.49
52-Week Range	27.49 - 27.51
Beta	1.54
Analysts	Sell
Price Target	19.67 (-28.45%)
Earnings Date	Nov 6, 2024

About SILK

Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid arte...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 4, 2019
• Employees: 474
• Stock Exchange: NASDAQ
• Ticker Symbol: SILK
• Website: https://silkroadmed.com

Financial Performance

In 2023, Silk Road Medical's revenue was $177.13 million, an increase of 27.77% compared to the previous year's $138.64 million. Losses were -$55.74 million, 1.33% more than in 2022.

Analyst Forecast

According to 9 analysts, the average rating for SILK stock is "Sell." The 12-month stock price forecast is $19.67, which is a decrease of -28.45% from the latest price.

Price Target

$19.67

(-28.45% downside)

Analyst Consensus: Sell